HUMA Humacyte, Inc.

8-K Current Report

Filed: March 19, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Humacyte, Inc. (HUMA) 8-K current report filed with SEC EDGAR on March 19, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Registered direct offering of 25 million shares of common stock at $0.80 per share, raising gross proceeds of $20 million
• Net proceeds expected around $18.4 million after placement agent fees and expenses

+3 more insights

Item 7.01 · Regulation FD Disclosure

• Disclosure clarifies 7.01 filing not “filed” under Exchange Act Section 18 liability provisions
• Information not incorporated by reference in future Securities Act or Exchange Act filings

+1 more insights

Other Humacyte, Inc. 8-K Filings

8-K Mar 19, 2026

Get deeper insights on Humacyte, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.